|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Asociación para Evitar la Ceguera en México |
|---|---|
| Information provided by: | Asociación para Evitar la Ceguera en México |
| ClinicalTrials.gov Identifier: | NCT00600301 |
Purpose
Diabetic macular edema is the most common cause of visual loss among patients with diabetic retinopathy. Pars plana vitrectomy has been reported to be effective for the treatment of diabetic macular edema. Previous report showed a limited improvement in visual acuity and macular thickness posterior intraoperative triamcinolone acetonide. Bevacizumab intravitreal injection has been proven be effective in the treatment of diabetic macular edema, in recent publications. The purpose of this study is to evaluate whether vitrectomy with and without intravitreal triamcinolone acetonide and bevacizumab injection affects vision outcome and macular thickness in patients with diabetic macular edema.
| Condition | Intervention | Phase |
|---|---|---|
|
Diffuse Diabetic Macular Edema |
Drug: Triamcinolone Acetonide and Bevacizumab |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Eligibility| Ages Eligible for Study: | 20 Years to 90 Years |
| Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Maximiliano Gordon, MD | 10841400 ext 1171, 1172 | retinamex@yahoo.com |
| Mexico, D.F. | |
| Asociacion Para Evitar la Ceguera en Mexico | Recruiting |
| Mexico D.F., D.F., Mexico, 04030 | |
| Contact: Maximiliano Gordon, MD 10841400 ext 1171, 1172 retinamex@yahoo.com | |
| Principal Investigator: | Maximiliano Gordon, MD | APEC |
More Information
| Study ID Numbers: | APEC-OO13 |
| Study First Received: | June 30, 2006 |
| Last Updated: | January 23, 2008 |
| ClinicalTrials.gov Identifier: | NCT00600301 History of Changes |
| Health Authority: | Mexico: Secretaria de Salud |
|
Macula Edema |
|
Anti-Inflammatory Agents Immunologic Factors Hormone Antagonists Eye Diseases Hormones, Hormone Substitutes, and Hormone Antagonists Edema Macular Degeneration Retinal Degeneration Triamcinolone diacetate Bevacizumab |
Angiogenesis Inhibitors Immunosuppressive Agents Hormones Glucocorticoids Triamcinolone hexacetonide Macular Edema Signs and Symptoms Triamcinolone Acetonide Triamcinolone Retinal Diseases |
|
Anti-Inflammatory Agents Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Edema Bevacizumab Hormones Triamcinolone hexacetonide Signs and Symptoms Macular Edema Triamcinolone Acetonide Therapeutic Uses |
Triamcinolone Growth Inhibitors Angiogenesis Modulating Agents Retinal Diseases Growth Substances Eye Diseases Retinal Degeneration Macular Degeneration Triamcinolone diacetate Enzyme Inhibitors Glucocorticoids Immunosuppressive Agents Angiogenesis Inhibitors Pharmacologic Actions |
